Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial-Reference-Cited by-同舟云学术

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

Published:2014-12-23 Issue:5 Volume:21 Page:1071-1077
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Choueiri Toni K.,Figueroa David J.,Fay André P.,Signoretti Sabina,Liu Yuan,Gagnon Robert,Deen Keith,Carpenter Christopher,Benson Peter,Ho Thai H.,Pandite Lini,de Souza Paul,Powles Thomas,Motzer Robert J.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression;Medical Sciences;2024-09-13

2. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810;Journal of Clinical Oncology;2024-06-10

3. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway;Cancer Biomarkers;2024-05-28

4. Targeting tumor-associated macrophages to reverse antitumor drug resistance;Aging;2024-05-23

5. Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides;Nature Communications;2024-04-09